Adaptimmune was facing a financing cliff until Galapagos walked in with a sprawling licensing deal for a next-generation T-cell therapy that could total $665 million. The multipronged deal, announced after market close Thursday, involves uza-cel, a MAGE-A4 TCR T-cell therapy Adaptimmune is developing for ovarian cancer. Galapagos, however, wants to take the therapy into head and neck cancer and potentially additional solid tumors down the line. Source: Fierce Biotech 31/5/2024